Obalon Therapeutics (NASDAQ:OBLN) Posts Earnings Results
Obalon Therapeutics (NASDAQ:OBLN) announced its earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.24), MarketWatch Earnings reports. Obalon Therapeutics had a negative return on equity of 115.36% and a negative net margin of 694.12%. The business had revenue of $0.70 million for the quarter.
Shares of NASDAQ:OBLN traded down $0.02 on Friday, reaching $0.68. 146,617 shares of the company’s stock were exchanged, compared to its average volume of 293,249. The company has a fifty day moving average of $0.77 and a 200-day moving average of $1.09. Obalon Therapeutics has a twelve month low of $0.62 and a twelve month high of $5.97. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.97 and a current ratio of 2.17.
About Obalon Therapeutics
Featured Article: Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.